1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Mental health and behavioural conditions
  5. Bipolar disorder

Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder

Technology appraisal guidance [TA292] Published date: 24 July 2013

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
  • Overview
  • 1 Guidance
  • 2 The technology
  • 3 The manufacturer's submission
  • 4 Consideration of the evidence
  • 5 Implementation
  • 6 Related NICE guidance
  • 7 Review of guidance
  • 8 Appraisal Committee members, guideline representatives and NICE project team
  • 9 Sources of evidence considered by the Committee
  • Changes after publication
  • About this guidance
Download guidance (PDF)

Guidance

  • Next

6 Related NICE guidance

6 Related NICE guidance

Details are correct at the time of publication. Further information is available on the NICE website.

  • Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years. NICE technology appraisal guidance 213 (2011).

  • Bipolar disorder. NICE clinical guideline 38 (2006).

  • Depression in children and young people. NICE clinical guideline 28 (2005).

  • The clinical effectiveness and cost effectiveness of electroconvulsive therapy (ECT) for depressive illness, schizophrenia, catatonia and mania. NICE technology appraisal guidance 59 (2003).

  • National Institute for Health and Care Excellence (NICE)

  • Next